Drugs / BAY2328065
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04851483 | Apr → Dec 2021 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04027192 | Jul 2019 → Sep 2020 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03427788 | Mar → Oct 2018 | endometriosis | Bayer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2328065 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03427788 ↗ |
| Action | Inhibit | “BAY2328065, works by blocking a certain protein that causes pain and swelling of the tissue and is thought to play a role in endometriosis.” NCT04851483 ↗ |
| Route | Oral | “single oral doses of BAY2328065” NCT03427788 ↗ |